News

A new transgenic Parkinson’s disease mouse model is able to recapitulate the motor symptoms and biological causes of disease, including alpha-synuclein protein aggregation, a study reports. Similar to Parkinson’s patients, this model also responds to levodopa, one of the main compounds used to treat symptoms of the disease. The study, “Abrogating Native…

Specific motor symptoms in Parkinson’s disease have a corresponding cognitive profile, with the tremor-dominant type being associated with less severe cognitive decline, a study reports. The study, “Cognitive decline in Parkinson’s disease: the impact of the motor phenotype on cognition,” was published in the Journal of Neurology,…

PhotoPharmics’s Spectramax light therapy reduces disease severity, lessens non-motor symptoms, and improves the quality of life of Parkinson’s patients, according to recent results of a controlled clinical study. The study,“Double-blind controlled trial of Spectramax™ light therapy for the treatment of Parkinson’s disease patients on stable dopaminergic…